Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Rebif is the leader in new prescription growth with a 22.4% share, an all-time high, at the end of March, Serono says. The company is focusing marketing of Rebif on efficacy, a message to which Tysabri helped draw attention. Serono expects Rebif to emerge as the global MS leader by 2006.